A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials that are informing treatment decisions.
Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.
Stream a wide selection of movies and TV shows for free on wedotv. No subscription needed – just hit play and enjoy unlimited entertainment!
We summarize the results of the complete analysis from the AALL1931 trial assessing the efficacy and safety of JZP458 in children and adult patients with…
Ruhnke et al. published a retrospective cohort study in Blood Advances validating the prognostic value of the 2022 ELN classification in patients with newly diagnosed…
Icro Meattini, MD, University of Florence, Florence, Italy, comments on the current treatment strategies for patients after breast cancer surgery, highlighting the optimization of de-escalation…
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, presents the results of a Phase II investigator-initiated study (NCT04998669) investigating a combination of loncastuximab tesirine…
Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
Key PointsCD37 is a surface receptor present on most AML blasts, which has unique internalization properties when compared with normal blood cells.Treatmen
PURPOSEDenileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial…
Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.
